MRK (Merck & Co., Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by MRK officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-13 | Jennifer Zachary | EVP, General Counsel | MIXED | — | — |
| 2026-08-13 | Chirfi Guindo | EVP, Access, Policy & Comms | Sell | — | — |
| 2026-08-12 | Richard R. DeLuca | EVP&Pres, Merck Animal Heallth | Sell | — | — |
| 2026-08-10 | Richard R. DeLuca | EVP&Pres, Merck Animal Heallth | Sell | — | — |
| 2026-08-07 | David R. Maraldo | EVP & Pres. MMD | MIXED | — | — |
| 2026-08-07 | Chirfi Guindo | EVP, Access, Policy & Comms | Sell | — | — |
| 2026-08-07 | David Michael Williams | EVP,Chief Info&Digital Officer | MIXED | — | — |
| 2026-08-07 | Chirfi Guindo | EVP, Access, Policy & Comms | Sell | — | — |
| 2026-08-07 | David R. Maraldo | EVP & Pres. MMD | MIXED | — | — |
| 2026-08-07 | David Michael Williams | EVP,Chief Info&Digital Officer | MIXED | — | — |
| 2026-07-01 | Surendralal Lanca Karsanbhai | Director | A | — | — |
| 2026-07-01 | Mary Ellen Coe | Director | A | — | — |
| 2026-07-01 | Christine E Seidman | Director | A | — | — |
| 2026-06-02 | DOUGLAS M BAKER JR | Director | A | — | — |
| 2026-06-02 | Pamela J. Craig | Director | A | — | — |
| 2026-06-02 | THOMAS H GLOCER | Director | A | — | — |
| 2026-06-02 | RISA J LAVIZZO-MOUREY | Director | A | — | — |
| 2026-06-02 | Stephen Mayo | Director | A | — | — |
| 2026-06-02 | Paul Rothman | Director | A | — | — |
| 2026-06-02 | PATRICIA F RUSSO | Director | A | — | — |
| 2026-06-02 | Christine E Seidman | Director | A | — | — |
| 2026-06-02 | INGE G THULIN | Director | A | — | — |
| 2026-06-02 | Mary Ellen Coe | Director | A | — | — |
| 2026-06-02 | Surendralal Lanca Karsanbhai | Director | A | — | — |
| 2026-06-02 | Kathy J Warden | Director | A | — | — |
| 2026-05-07 | Chirfi Guindo | EVP, Access, Policy & Comms | A | — | — |
| 2026-05-07 | Dalton E. Smart III | SVP Fin. - Global Controller | A | — | — |
| 2026-05-07 | Johannes Jacobus Oosthuizen | EVP, Oncology & Int?l | A | — | — |
| 2026-05-07 | David R. Maraldo | EVP & Pres. MMD | A | — | — |
| 2026-05-07 | Brian Foard | EVP, Specialty, Pharma, & ID | A | — | — |
| 2026-05-07 | Robert M Davis | Chairman, CEO & President | A | — | — |
| 2026-05-07 | Richard R. DeLuca | EVP&Pres, Merck Animal Heallth | A | — | — |
| 2026-05-07 | Betty D Larson | EVP, Chief HR Officer | A | — | — |
| 2026-05-07 | Dean Y Li | Executive VP & President, MRL | A | — | — |
| 2026-05-07 | Caroline Litchfield | EVP & CFO | A | — | — |
| 2026-05-07 | David Michael Williams | EVP,Chief Info&Digital Officer | A | — | — |
| 2026-05-07 | Jennifer Zachary | EVP, General Counsel | A | — | — |
| 2026-05-05 | David R. Maraldo | EVP & Pres. MMD | MIXED | — | — |
| 2026-05-05 | Dalton E. Smart III | SVP Fin. - Global Controller | MIXED | — | — |
| 2026-05-01 | Johannes Jacobus Oosthuizen | EVP, Oncology & Int?l | MIXED | — | — |
| 2026-05-01 | Robert M Davis | Chairman, CEO & President | MIXED | — | — |
| 2026-05-01 | Caroline Litchfield | EVP & CFO | MIXED | — | — |
| 2026-05-01 | Betty D Larson | EVP, Chief HR Officer | MIXED | — | — |
| 2026-05-01 | Jennifer Zachary | EVP, General Counsel | MIXED | — | — |
| 2026-05-01 | Dean Y Li | Executive VP & President, MRL | MIXED | — | — |
| 2026-05-01 | Dalton E. Smart III | SVP Fin. - Global Controller | MIXED | — | — |
| 2026-05-01 | David Michael Williams | EVP,Chief Info&Digital Officer | MIXED | — | — |
| 2026-05-01 | Richard R. DeLuca | EVP&Pres, Merck Animal Heallth | MIXED | — | — |
| 2026-05-01 | Sanat Chattopadhyay | Exe V-P & Pres. MMD | MIXED | — | — |
| 2026-05-01 | Chirfi Guindo | EVP, Access, Policy & Comms | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Executive Chair | 915,989 | — |
| — | Chairman, CEO & President | 450,350 | — |
| — | Exec.V.P.& C.F.O. | 232,728 | — |
| — | Exe V-P & Pres, MRL | 215,059 | — |
| — | EVP & Pres-Global Human Health | 200,540 | — |
| — | Exe V-P & Pres, MRL | 190,957 | — |
| — | Exe V-P & Gen Counsel | 150,432 | — |
| — | Exe V-P & CFO | 149,553 | — |
| — | Chairman | 135,777 | — |
| — | Exe V-P & Pres. MMD | 134,478 | — |
| — | EVP&Pres, Merck Animal Heallth | 111,488 | — |
| — | Exe VP&Chief Ethics & ComplOff | 104,670 | — |
| — | EVP & Pres ? Human Health | 100,037 | — |
| — | Executive VP & President, MRL | 94,431 | — |
| — | EVP & CFO | 92,300 | — |
| — | ExVP&PresConsHlthCare | 83,765 | — |
| — | Exe V-P Global Srvs & CIO | 83,041 | — |
| — | Exe V-P, HR | 80,433 | — |
| — | Exe Vice President | 75,628 | — |
| — | EVP, Chief HR Officer | 74,313 | — |
| — | EVP, General Counsel | 69,786 | — |
| — | Exe V-P & Pres. MMD | 68,764 | — |
| — | President, MV & ID | 57,471 | — |
| — | SVP Chief Ethics & Com Officer | 56,998 | — |
| — | Senior Vice President | 50,783 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MRK quote page; the site-wide leaderboard is on the insider transactions hub.